On June 15, 2016 Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, reported that data from a large single hospital experience conducted at Southampton University Hospital in the United Kingdom has been accepted for oral presentation at the 6th European Post-Chicago Melanoma/Skin Cancer Meeting to be held in Munich, Germany at the Leonardo Royal Hotel from June 30 – July 1, 2016 (Press release, Delcath Systems, JUN 15, 2016, View Source;p=RssLanding&cat=news&id=2177653 [SID:1234513355]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract authored by I. Karydis, et al. is titled, "Chemosaturation via percutaneous hepatic perfusion – an update on a single centre experience of treating metastatic uveal melanoma." Additional information about the Post-Chicago scientific program can be found here and the complete abstract will be available for download approximately 10 days prior to the congress.